Study of Bio-Chemical parameters Humanofort – Tables

The variations of total cholesterol from the plasma of the studied group, men, before and after 2 months of treatment with Humanofort (4 capsules/day).

Normal values: less than 200 mg/dl

Nr

Name

Initial (mg)

After 2 months

Variations

Observations

1

Olinescu Radu

275

254

– 24

2

Georgescu Ghe.

279

238

– 41

3

Teodoriu Alex.

243

211

– 33

4

Racu Constantin

254

223

– 31

5

Cristea Gheorghe

335

284

– 51

6

Comişel Virgiliu

253

203

– 50

7

Liuşnea Octav.

285

226

– 59

8

Lixandru Petre

201

191

– 10

9

Pană Gheorghe

224

204

– 20

10

Aldescu Viorel

224

207

– 17

11

Bartoş Emil

295

210

– 85

12

Pitea Simion

286

249

– 37

13

Teodorescu Emil

314

276

– 38

14

Agiu Marian

163

149

– 14

15

Alexandru Const.

199

193

– 6

16

Murariu Adi. Mariu

202

173

– 29

17

Ioniţă Gheorghe

191

184

– 7

Total, mg 4223 3675 – 548

Mean, mg 248,4 216 – 32,3

Conclusions: In all investigated men, older than 50 years, total cholesterol was higher than normal values. After treatment with Humanofort, in all men, total cholesterol has decreased, with a mean of 32 mg, towards physiological range.The decrease of cholesterol was higher as the initial values were more increased.

The variations of the total cholesterol in the plasma of the studied group, women, older women older than 50 years, before and after treatment with Humanofort (4 capsules/day for 2 months).

Normal values, less than 200 mg/dl

Nr

Name

Initial values

After Treatment

Variations

1

Olinescu Victoria

233

204

– 29

2

Ignat Aurica

270

215

– 55

3

Gheorghe Georgeta

364

315

– 49

4

Ghiuţă Monica

194

184

– 10

5

Melacrinos Floarea

243

213

– 30

6

Georgescu Floarea

331

285

– 46

7

Zaharia Florina

255

230

– 25

8

Stoenescu Antonela

268

183

– 85

9

Dundaru Georgeta

277

258

– 19

10

Teodoriu Aneta

245

229

– 16

11

Popa Rodica

254

212

– 42

12

Comişel Ecaterina

278

226

– 52

13

Stefanovici Iasmina

379

368

– 11

14

Pitea Ludovica

270

246

– 24

15

Teodorescu Maria

422

405

– 17

16

Ionescu Maria

198

174

– 24

17

Zamfirescu Georgeta

235

175

– 60

18

Vătăman Rodica

317

307

– 10

Tiroidectomie

19

Ghiuţă Oana

347

346

– 1

20

Burtan Mariana

221

207

– 14

21

Păun Aurica

250

232

– 18

22

Dănilă Ana

174

161

– 13

Total, mg

6025

5375

– 650

Mean , mg

274

244

29,5

Conclusions: With two exceptions, all women have increased initial values of total cholesterol. After treatment, the total cholesterol has decreased in all women with a mean of 29,5 mg for the entire lot. In 5 women with high initial cholesterol (cases 2,3,6,8,11,12), the decrease of cholesterol after treatment had a mean of 50 mg. In 3 women with initial cholesterol higher than 300 mg, the decrease after treatment was low, but all were in almost pathological conditions. But, anyway, in all women treated, cholesterol has decreased, with a trend towards the upper physiological range. Humanofort has induced a regulatory effect.

The variations of LDL Cholesterol in men, before and after treatment with Humanofort  (4 capsules/day for 2 months).

Normal values: less than 130 mg/dl

Nr

Name

Initial values

After Treatment

Variations

1

Olinescu Radu

175

149

– 26

2

Georgescu Gheorghe

203

158

– 45

3

Teodoriu Alexandru

174

140

– 34

4

Racu Constantin

99

116

– 17

5

Cristea Gheorghe

228

178

– 50

6

Comişel Virgiliu

176

131

– 45

7

Liuşnea Octavian

188

134

– 54

8

Lixandru Petre

116

127

– 11

9

Pană Gheorghe

160

134

– 26

10

Aldescu Viorel

146

114

– 32

11

Bartoş Ionel

177

105

– 72

12

Pitea Simion

201

153

– 48

13

Teodorescu Emil

238

187

– 51

14

Alexandru Constantin

90

74

– 16

15

Murariu Adi Marius

112

85

– 27

16

Ioniţă Gheorghe

107

87

– 20

Mean value for 16 men

156.8

Mean value for 14 men: 145 mg. For all 14 men, LDL cholesterol has decreased after treatment with Humanofort with a mean of 39 mg

Conclusions: From a group of 16 men, the administration of Humanofort has decreased LDL cholesterol (bad cholesterol) in 14 subjects (89 %) with a mean of 39 mg. In 2 men, the administration of Humanofort induced a slight increase of 14 mg (mean) of LDL. In these 2 men, the initial values of LDL were decreased (mean 107 mg), as compared with that of the majority (mean 145 mg). Therefore, the administration of Humanofort triggered a trend towards normal range In 7 men, with high initial values of LDL, the administration of Humanofort has induced an impressive decrease of LDL more than 45 mg Again, a regulatory effect of Humanofort.

The variations of LDL cholesterol (bad cholesterol) in the plasma of women, before and after the administration of Humanofort (4 capsules/day for 2 months).

Normal values: less than 130 mg/dl

Nr

Name

Initial values

After Treatment

Variations

1

Olinescu Victoria

153

114

– 39

2

Ignat Aurica

127

89

– 38

3

Gheorghe Georgeta

258

198

– 60

4

Ghiuţă Monica

113

107

– 6

5

Melacrinos Floarea

141

119

– 22

6

Georgescu Floarea

218

180

– 38

7

Zaharia Florina

169

149

– 20

8

Dundaru Georgeta

182

176

– 6

9

Teodoriu Aneta

158

127

– 31

10

Popa Rodica

157

127

– 30

11

Comişel Ecaterina

183

141

– 42

12

Stefanovici Iasmina

305

265

– 40

13

Pitea Ludovica

164

142

– 22

14

Ionescu Maria

112

91

– 21

15

Zamfirescu Georgeta

138

88

– 50

16

Vătăman Rodica

218

211

– 7

17

Ghiuţă Oana

266

235

– 31

18

Burtan Mariana

144

119

– 25

19

Păun Aurica

180

147

– 33

20

Dănilă Ana

94

84

– 10

Total, mean (mg) 174 140,5 34

Conclusions: For all women investigated, The initial mean value of LDL cholesterol was 174 mg/dl, moderatedly increased as compared with normal values. From all group, only 4 women have normal initial values, while 5 women have LDL values higher than 200 mg/dl.

The administration of Humanofort has induced a definetly decrease of LDL cholesterol with a mean of 34 mg/dl In 10 women, the decrease of LDL cholesterol was higher than 35 mg. In 4 women with initial values of LDL higher than 200, the administration of Humanofort has induced a decrease od more than 40 mg. As in the case of men, the administration of Humanofort has induced an adaptative, regulator effect.

The variations of CARDIOVASCULAR RISK FACTORS according to the recommended studies of AETHNA-2000 PROGRAM for the group of men, before and after administration of Humanofort (4 caps/day for 2 months). The detailed interpretation of Risk Factors were presented after the table. The following Risk Factors were studied: Total Cholesterol/HDL (TC/HDL) and ApoLipoprotein B/ApoLipoprotein A-1 (ApoB/A)

Nr

Name

Initial

CT/HDL ApoB/A

After CT/HDL ApoB/A

Variations CT/HDLApoB/A

Observ.

1

Olinescu Radu

3.4 0.73

2.9 0.62

-0.5 -0.11

2

Georgescu Gheorghe

5.6 0.83

4.3 0.57

-1.3 -0.26

3

Teodoriu Alexandru

5.8 1.29.

5.02 0.92

-0.8 +0.37

4

Racu Constantin

6.1 0.98

5.3 0.89

-0.8 -0.09

5

Cristea Gheorghe

6.7 1.14

6.5 0.82

-0.02 -0.32

6

Comişel Virgiliu

5.1 0.71

3.5 0.57

-1.6 -0.14

7

Liusnea Octavian

3.7 0.56

2.8 0.45

-0.9 -0.11

8

Lixandru Petre

5.0 0.89

3.8 0.59

-1.2 -0.30

9

Pană Gheorghe

5.3 1.11

4.4 0.75

-0.9 -0.35

10

Aldescu Viorel

6.05 1.16

5.9 1.08

-0.2 -0.08

11

Bartoş Ionel

3.5 0.68

2.5 0.40

-1.0 -0.28

12

Pitea Simion

5.1 0.73

4.4 0.75

-0.7 +0.02

13

Teodorescu Emil

6.3 1.31

4.5 0.44

-1.8 -0.57

14

Agiu Marian

4.4 0.76

4.4 0.74

0.0 -0.02

15

Alexandru Constantin

4.6 1.01

3.8 0.72

-0.8 -0.19

16

Murariu Adi Marius

3.06 0.52

2.4 0.76

-0.5 + 0.24

17

Ioniţă Gheorghe

2.6 0.38

2.3 0.53

-0.3 +0.15

Mean, mg

4.84 0.84

4.04 0.80

-0.80

Cardiovascular Risk Factors: Recommended Limits for men – AETHNA-2000:

CV Risk Total Cholesterol/HDL ApoB/ApoA

Lowest (less than 10%) Less than 3.8 less than 0.69

Low (less than 27%) 3.9 – 4.7 0.70 – 0.90

Moderate (51 – 75 %) 4.8 – 5.9 0.95 – 1.22

High (76 – 89 %) 6.0 – 6.9 1.25 – 1.48

Highest (less than 90%) Higher than 7.0 Higher than 1.50

Conclusions: According to the limits mentioned above, in the group of investigated men (17), 4 men were within high risk range (cases 4,5,10,13) according to the first risk ratio, but according to the second, only 2 (cases 3 and 13). Anyway, even for mean ratios, the first risk factor) total cholesterol/HDL was more severe, as for entire group, the mean ratio was 4.84 /moderate), while for the second, Apo Lipoprotein (B/A), the mean ratio was 0.84 (low range)

The administration of Humanofort produced an impressive decrease, (100%), a clear-cut effect for the first risk factor, decreased with a mean of o.84. After treatment, for the entire group, only one case (nr.5) remained within highrisk range. The decreasing effect of Humanofort was effective for the entire group of men. In 5 cases (2,6,8,11,13), 31 % the decrease was higher than 1.0. For the second risk factor, Lipoproteins B/A, the decreasing effect of Humanofort was present in 12 men (70 %) in a wide range, while for 5 men (30 %), a slight increase, mean of (18) was noticed, without a possible correlation with their health condition.

The variations of the RISK FACTORS FOR CARDIOVASCULAR DISEASES for women, according to the recommendation of AETHNA-2000 PROGRAM, before and after the treatment with Humanofort (4 capsules/day for 2 months)

Nr

Name

Initial CT/HDL Apo B/A

After treatment CT/HDL Apo B/A

Variations CT(HDL Apo B/A

Obs

1

Olinescu Victoria

3.75 0.83

2.75 0.47

-1.0 -0.36

2

Ignat Aurica

3.03 0.35

2.15 0.56

-0.9 -0.26

3

Gheorghe Georgeta

4.85 0.72

3.76 0.73

-1.09 +0.01

4

Ghiuţă Monica

3.28 0.67

3.28 0.46

0.0 -0.21

5

Melacrinos Floarea

4.5 0.72

4.4 0.71

-0.1 -0.01

6

Georgescu Floarea

4.3 0.21

3.5 0.52

-0.8 + 0.31

7

Zaharia Florina

4.04 0.72

3.77 0.66

-0.27 -0.06

8

Stoenescu Antonela

7.4 0.58

5.3 0.95

-1,9 +0.37

9

Dundaru Georgeta

4.3 —

3.8 —

-0.5

10

Teodoriu Aneta

4.4 0.86

5.3 0.80

+0.7 -0.06

11

Popa Rodica

4.1 0.58

3.1 0.80

-1.0 +0.22

12

Comişel Ecaterina

4.5 1.15

3.9 0.79

-0.6 -0.36

13

Stefanovici Iasmina

8.3 1.49

6.8 1.21

-1.5 -0.21

14

Pitea Ludovica

3.0 0.44

3.07 0.52

+0.07 +0.08

15

Teodorescu Maria

6.1 2.57

4.6 0.76

-1.4 -1.81

16

Ionescu Maria

2.64 0.40

2.5 0.38

-0.14 -0.02

17

Zamfirescu Georgeta

2.85 0.52

3.24 0.76

+0.39 +0.24

18

Vătăman Rodica

4.17 0.70

4.37 0.90

+0.27 +0.20

19

Ghiuţă Oana

8.46 2.02

4.5 1.12

-4.0 -1.9

20

Burtan Mariana

4.1 0.98

3.2 0.52

-0.9 -0.46.

21

Păun Aurica

5.68 0.74

4.8 0.61

-0.88 -0.13

22

Dănilă Ana

5.11 —

4.6 0.86

-0.5 —

Mean, mg

4.49 (20) 1.73

3.80 (20)1.02

CARDIOVASCULAR RISK FACTORS, limits recommended by AETHNA-2000 PROGRAM for women

CV RISK Total Cholesterol/HDL LipoProtein B/A

Lowest (less than 10%) Less than 2.9 Less than 0.47

Low (less than 27%) 3.0 — 3.6 0.49 – 0.60

Moderate: 51-75% 3.7 — 4.6 0.66 – 1.152

High 76-89% 4.7 – 5.6 0.92 – 1.16

Highest 90% Higher than 5.7 Higher than 1.17

Conclusions: In the entire lot of investigated women, at the initial values, for the first ratio factor (CT/HDL) there were 4 with the highest risk (cases 8, 13, 15, 19). For the second ratio (LipoB/A), there were 4 with the highest risk (cases 12, 13, 15, 19); the last three were common. For moderate CV risk, for both ratios there were common 5 cases (1,3,5,21,22), the second ratio contained more (9 cases).

The administration of Humanofort decreased the first risk factor in 18 cases (82 %). In these 18 women (82%), the CT/HDL ratio decreased in mean of 1.01, while for the 4 women, the this factor increased with a mean of 0.92. The administration of Humanofort decreased the second risk factor Lipoproteins B/A in 12 women (60 %) with a mean of 1.3, while for the 6 women, this factor increased with a mean of 0.75. The odd variation (increase of risk factors in three women (cases 14, 17, 18) is not related with the magnitude of risk factors, but rather for individual constitutions For both Cardiovascular risk factors, the administration of Humanofort induced a clear-cut effect, a variation towards the physiological range.

The variations of INSULIN in men, before and after administration of Humanofort  (4 capsules/day for 2 months).

Normal range: 2.60 — 25uU/ml

Nr

Name

Initial value

After Treatment

Variations

1

Olinescu Radu

4.70

9.81

+5.11

2

Georgescu Gheorghe

2.39

1.94

– 0.45

3

Teodoriu Alexandru

17.49

15.96

– 1.53

4

Racu Constantin

30.91

4.80

-25.11

5

Cristea Gheorghe

14.70

11.06

– 3.64

6

Comişel Virgiliu

4.49

2.51

– 1.98

7

Liuşnea Octavian

6.25

6.23

– 0.02

8

Lixandru Petre

27.50

9.66

– 19.94

9

Pană Gheorghe

10.03

9.57

– 0.06

10

Aldescu Viorel

7.26

16.66

+9.40

11

Bartoş Ionel

7.29

0.29

– 7.0.

12

Pitea Simion

4.49

3.00

– 1.49

13

Teodorescu Emil

3.10

4.04

+0.94

14

Agiu Marian

19.54

3.89

-15.65

15

Alexandru Constantin

11.53

2.90

– 9.63

16

Murariu Adi Marius

3.74

2.31

– 1.43

17

Ioniţă Gheorghe

6.03

3.73

– 2.30

Mean, uU/ml

10.04

6.03

Conclusions: The administration of Humanofort in 17 men produced a decrease of insulin level in 14 men (82 %) with a mean of 5.18 uU/ml. In 3 men, an increased effect was noticed, with a mean of 5.15uu/ml. The decreasing effect produced by Humanofort was higher in 4 cases (4, 8, 14, 15), as the initial insulin levels were higher than the mean. In these particular cases the insulin concentration dropped with a mean of 17uu/ml.

The variations of INSULIN LEVEL in women, before and after the administration of Humanofort (4 caps a day for 2 months).

The normal range: 2.60 — 25uu/ml

Nr

Name

Initial value

After Treatment

Variations

1

Olinescu Victoria

5.62

3.38

– 2.24

2

Ignat Georgeta

7.20

6.77

– 0.43

3

Gheorghe Georgeta

10.50

15.10

+5.40

4

Ghiuţă Monica

9.61

10.05

+0.44

5

Melacrinos Floarea

8.78

12.87

+4.09

6

Georgescu Floarea

2.72

5.01

+2.29

7

Zaharia Florina

4.66

5.24

+0.58

8

Stoenescu Antonela

14.09.

14.69

+0.60

9

Dundaru Georgeta

5.64

5.92

+0.28

10

Teodoriu Aneta

7.86

3.76

– 4.10

11

Popa Rodica

1.52

31.67

+30.15

12

Comişel Ecaterina

27.91

8.20

-19.71

13

Stefanovici Iasmina

21.19

0.73

-19.46

14

Pitea Ludovica

4.56

2.96

– 2.40

15

Teodorescu Maria

2.74

1.04

– 1.70

16

Ionescu Maria

8.94

7.08

– 0.86

17

Zamfirescu Georgeta

4.69

5.71

+ 1.02

18

Vătăman Rodica

4.16

6.20

+ 2.04

19

Ghiuţă Oana

14.62

10.18

– 3.44

20

Burtan Mariana

3.85

3.82

– 0.03

21

Păun Aurica

12.40

16.21

+ 3.81

22

Dănilă Ana

6.09

7.36

+ 1.25

Total mean, uu/ml

8.60

8.36

Conclusions: The administration of Humanofort in women produced widespread effects. In 10 women (45 %), the insulin level decreased with a mean of 4.44 uu/ml. But for the rest (55 %) an increase of the insulin was observed with a mean of 4.33 uu/ml. Contrarily, as compared with the investigated group of men, in the same conditions, the administration of Humanofort in women produced an apparent regulatory effect, as function of the initial value and the health conditions. For example, in the cases 12 and 13, with very high initial levels, the insulin concentration droped spectacularly with approx. 19. 5uu/ml. A contrary effect was observed for case 11, as the initial level of insulin was below physiological range, but after the administration of Humanofort increased to an upper level of 32uu/ml. Therefore, the regulatory effect of Humanofort on the insulin level is emphasized on both men and women.

The variations of IGF (Insulin-like Growth Factor) or Somatomedin C in men, before and after the administration of Humanofort (4 caps a day for 2 months).

Normal values: 64 — 188ng/ml

Nr

Name

Initial

After Treatment

Variations

1

Olinescu Radu

153

143

– 10

2

Georgescu Gheorghe

182

186

+ 4

3

Teodoriu Alexandru

117

73.6

– 43.4

4

Racu Constantin

223

137

– 86

5

Cristea Gheorghe

104

144

+40

6

Comişel Virgiliu

175

118

– 57

7

Liuşnea Octavian

168

137

– 31

8

Lixandru Petre

171

168

– 3

9

Pană Gheorghe

239

206

– 33

10

Aldescu Viorel

347

256

– 91

11

Bartoş Ionel

188

119

– 69

12

Pitea Simion

142

114

– 28

13

Teodorescu Emil

111

116

+ 4

14

Agiu Marian

176

141

– 35

15

Alexandru Constantin

441

112

-329

16

Murariu Adi Marius

486

150

-330

17

Ioniţă Gheorghe

182

229

+ 47

18

Mihăescu Gheorghe

453

162

-291

Mean ng/ml 222.3 151 77.3 21

Conclusions: In the group of 18 men, there were 5 (29 %) with initial values of IGF higher than 200ng/ml. The administration of Humanofort produced a clear-cut decreasing effect with a mean of 77 ng/ml in 14 subjects /77 %). But the most spectacular effect of Humanofort was the regulatory, as in all 5 subjects with initial very high values, the concentration of IGF returned to the normal range. In three cases (25, 16, 18), after the administration of Humanofort, the level of IGF droped with 300 ng/ml

The variations of IGF (Insulin-like Growth Factor or Somatomedin C in women, before and after the administration of Humanofort (4 caps per day, for 2 months).

Normal values: 64 – 188 ng/ml

Nr

Name

Initial

After Treatment

Variations

1

Olinescu Victoria

437

89.1

– 347.9

2

Gheorghe Georgeta

436

99.6

– 336.4

3

Ghiuţă Monica

127

170

+ 43

4

Melacrinos Floarea

420

125

– 295

5

Georgescu Floarea

110

99

-. 11

6

Zaharia Florina

153

130

– 23

7

Stoenescu Antonela

193

128

– 65

8

Dundaru Georgeta

416

168

248

9

Teodoriu Aneta

98.3

39.3

– 59

10

Popa Rodica

184

145

– 39

11

Comişel Ecaterina

137

83.4

– 54

12

Stefanovici Iasmina

165

147

– 18

13

Pitea Ludovica

183

163

– 20

14

Teodorescu Maria

39.6

59.7

+ 20.1

15

Ionescu Maria

144

132

– 12

16

Zamfirescu Georgeta

110

96.6

– 10.4

17

Vătăman Rodica

129

162

+ 33

18

Ghiuţă Oana

149

200

+ 51

19

Burtan Mariana

109

154

+ 45

20

Păun Aurica

128

110

– 18

21

Dănilă Ana

397

76.1

– 320.9

Mean ng(ml

203

122.7

Conclusions: In the group of 21 women there were 5 (24 %) with very high initial values of IGF. After the administration of Humanofort, the level of IGF decreased (as mean) from 203 to 122.7 ng/ml in 16 women. The spectacular effect of Humanofort was regulatory, as for cases 1,3,5, 9, 21, the level of IGF droped with more than 250 ng/ml

CLINICAL PROFILE OF THE INVESTIGATED SUBJECTS

Captions: CV = Cardio Vascular Diseases; DsLip = Dislpidemic affections; Liver = liver affections; VSH = Sedimentation Rate of Erythrocytes; HT = Hypertensive

Men

Nr

Name

Age years

CV

DsLip

Diabetes

Liver

VSH

Observ.

1

Olinescu Radu

74

2.5

Thyroid troubles

2

Georgescu Ghe.

65

5

3

Teodoriu Alexandru

75

Vasc.

accident

11

CEA = 5.12

4

Racu Constantin

61

2 Infractus

Pres-ent

Present

42

Obesity, athero-sclerosis

5

Cristea Gheorghe

56

Cardiop.

Pres.

Present

15

Heart dis.

6

Comişel Virgiliu

68

4

7

Liuşnea Octav

66

5

8

Lixandru Petre

38

5

Arthrosis?

9

Pană Gheorghe

59

Hepatitis

5

10

Aldescu Viorel

57

Present

20

CEA = 2.6

11

Bartoş Ionel

68

9

12

Pitea Simion

75

23

Muscular affec.

13

Teodorescu Emil

68

Cardiop.

Present

9

14

Agiu Marian

49

10

CEA = 3.5

15

Alexandru Const.

59

15

16

Murariu Adi Mariu

71

10

CEA = 3.6

17

Ioniţă Gheorghe

59

5

CEA = 3.4, PSA =9

18

Mihăescu Ghe

67

Women

 

Nr

Name Age

CV

DisLip

Diabet

Liver–VSH

Observations

1

Olinescu Victoria 69

Cardiop.

7

Thrombocytosis

2

Ignat Anica 69

HT

12

CEA = 2.6

3

Gheorghe Gorgeta 69

Atheroscl.

Present

42

Obese, metab.troub

4

Ghiuţă Monica 65

11

5

Melacrinos Floare 73

Affec. 22

CEA = 2.8

6

Georgescu Floarea 83

HT

37

CEA = 1.94

7

Zaharia Florina 54

10

8

Stoenescu Antone 62

36

CEA = 3.53

9

Dundaru Georgeta 70

Present

40

Obese

10

Teodoriu Aneta 73

Vasc.acc.

32

CEA = 8

11

Popa Rodica 58

Affec 5

Hepatitis, CEA =6.8

12

Comişel Ecaterina 59

Cardiop.

38

Obsese, glaucoma

13

Stefanovici Iasmina 53

Present

40

Obese

14

Pitea Ludovica 71

23

Fibroma

15

Teodorescu Maria 65

HT

Present

25

Thyroid problems

16

Ionescu Maria 59

7

17

Zamfirescu George.63

10

18

Vătăman Rodica 49

HT

Present

10

19

Ghiuţă Oana 61

38

Thyroidectomia

20

Burtan Mariana 49

9

21

Păun Anica 57

6

22

Dănilă Ana 62

HT

Present

13

Obese,

Osteoporosis

GENERAL CONCLUSIONS AFTER THE ADMINISTRATION OF HUMANOFORT

Parameter

Sex

Principal variation

Mean

Regulatory effect

Total cholesterol

Men

Women

100% decrease

100% decrease

32.3 mg

29.5 mg

22% decrease 50 mg

23% decrease 50 mg

LDL cholesterol

Men

Women

89% decrease

100% decrease

39 mg

34 mg

11% increase in subjects with low initial values

10% decrease 40 mg

Risk factors TC/HDL

Men

Women

100% decrease (moderate, low)

82% decrease

23% decrease had highest risk, all reduced to moderate

0.84

1.01

4 cases with initial high risk were reduced to one

30% presented a slight increase or non-receptive

Apo B/A

Men

Women

70% decrease

60% decrease

0.80

0.75

30% regulatory increase

40% regulatory increase

Insulin

Men

Women

82% decrease

45% decrease

55% decrease

5.18 uU

4.44 uU

4.33 uU

In 4 cases the decrease was higher than 17 uU

Regulatory variations within physiological range

IGF

Men

Women

77% decrease (29% high values)

75% decrease (24% high values)

77 ng

80 ng

The increases were within physiological range

The administration of Humanofort induced a clear-cut variation of parameters investigated towards the physiological range. Generally, as the initial values were higher, the regulatory variations were also higher, mostly decrease; therefore, the regulatory effect of Humanofort was function of the initial values parameters. The same effect was also noticed with other parameters investigated, but not presented above, such as triglycerides, Cortisol, 17 ketosteroids, as well as some immunological: CEA, PSA and CRP (Protein C Reactive).

The interpretation of this study was performed by dr. Radu OLINESCU, Ph.D. Senior Scientist from the Clinical Hospital Fundeni, Department of Biochemistry, Bucharest and former Visiting Professor at Department of Nutrition, University of Illinois at Urbana Champaign, USA.